OBJECTIVES: Cost-effectiveness models for diabetes link glycated hemoglobin (HbA1c) to diabetes-related complications. Independent of diabetes-related complications, there is little known on the association between HbA1c and health utility scores. This link can alter the cost effectiveness of interventions designed to improve HbA1c. The cross-sectional relationship between HbA1c and health utility scores in adult type 1 diabetes patients was estimated after adjusting for diabetes-related complications. METHODS: The EuroQoL-5 dimension (EQ-5D) questionnaire and an ad hoc survey requesting demographic information and adherence to glucose monitoring therapies was administered to adult type 1 diabetes patients during a clinic visit and combined with clinical medical record data. Health utility scores were derived using the US time-tradeoff valuation of the EQ-5D. Linear regression was used to estimate the relationship between HbA1c and utility, adjusting for treatments, demographics, and diabetes-related complications. RESULTS: Among 176 patients, mean (standard deviation [SD]) age was 38 (12.2) years, duration of disease was 22 (12.1) years, and number of chronic conditions other than type 1 diabetes was 2.7 (2.0). Unadjusted mean (SD) utility was 0.94 (0.09) for those with HbA1c levels <7 % (n = 54), 0.89 (0.15) for those with HbA1c ≥ 7 % (n = 122), and 0.91 (0.14) for all patients. After adjustment, a 1 % absolute increase in HbA1c was associated with a disutility of -0.03 (95 % confidence interval [CI] -0.049, -0.006). CONCLUSIONS: Findings suggest that, after adjusting for diabetes-related complications, higher HbA1c levels are associated with a significant health disutility. Pending additional data from longitudinal studies, these findings could be used in cost-effectiveness evaluations of type 1 diabetes interventions that impact HbA1c.
OBJECTIVES: Cost-effectiveness models for diabetes link glycated hemoglobin (HbA1c) to diabetes-related complications. Independent of diabetes-related complications, there is little known on the association between HbA1c and health utility scores. This link can alter the cost effectiveness of interventions designed to improve HbA1c. The cross-sectional relationship between HbA1c and health utility scores in adult type 1 diabetespatients was estimated after adjusting for diabetes-related complications. METHODS: The EuroQoL-5 dimension (EQ-5D) questionnaire and an ad hoc survey requesting demographic information and adherence to glucose monitoring therapies was administered to adult type 1 diabetespatients during a clinic visit and combined with clinical medical record data. Health utility scores were derived using the US time-tradeoff valuation of the EQ-5D. Linear regression was used to estimate the relationship between HbA1c and utility, adjusting for treatments, demographics, and diabetes-related complications. RESULTS: Among 176 patients, mean (standard deviation [SD]) age was 38 (12.2) years, duration of disease was 22 (12.1) years, and number of chronic conditions other than type 1 diabetes was 2.7 (2.0). Unadjusted mean (SD) utility was 0.94 (0.09) for those with HbA1c levels <7 % (n = 54), 0.89 (0.15) for those with HbA1c ≥ 7 % (n = 122), and 0.91 (0.14) for all patients. After adjustment, a 1 % absolute increase in HbA1c was associated with a disutility of -0.03 (95 % confidence interval [CI] -0.049, -0.006). CONCLUSIONS: Findings suggest that, after adjusting for diabetes-related complications, higher HbA1c levels are associated with a significant health disutility. Pending additional data from longitudinal studies, these findings could be used in cost-effectiveness evaluations of type 1 diabetes interventions that impact HbA1c.
Authors: J Todd Coffey; Michael Brandle; Honghong Zhou; Deanna Marriott; Ray Burke; Bahman P Tabaei; Michael M Engelgau; Robert M Kaplan; William H Herman Journal: Diabetes Care Date: 2002-12 Impact factor: 19.112
Authors: Robert Brett McQueen; Marc D Breton; Joyce Craig; Hayden Holmes; Melanie D Whittington; Markus A Ott; Jonathan D Campbell Journal: J Diabetes Sci Technol Date: 2018-04-21
Authors: Jayne Smith-Palmer; Jay P Bae; Kristina S Boye; Kirsi Norrbacka; Barnaby Hunt; William J Valentine Journal: Clinicoecon Outcomes Res Date: 2016-10-07
Authors: R Brett McQueen; Cristy Geno Rasmussen; Kathleen Waugh; Brigitte I Frohnert; Andrea K Steck; Liping Yu; Judith Baxter; Marian Rewers Journal: Diabetes Care Date: 2020-04-23 Impact factor: 19.112
Authors: Robert Blissett; Deirdre Blissett; Fleur Levrat-Guillen; Harshal Deshmukh; Emma G Wilmot; Robert E J Ryder; Chris Walton; Thozhukat Sathyapalan Journal: BMJ Open Diabetes Res Care Date: 2022-03
Authors: Martin Ridderstråle; Lyndon Marc Evans; Henrik Holm Jensen; Mette Bøgelund; Marie Markert Jensen; Åsa Ericsson; Johan Jendle Journal: Health Qual Life Outcomes Date: 2016-01-22 Impact factor: 3.186